Moody Aldrich Partners’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,863	Closed	-$671K	–	224
2024 Q1	$671K	Hold	4,863	–	–	0.11%	127
2023 Q4	$641K	Hold	4,863	–	–	0.12%	125
2023 Q3	$547K	Buy	+4,863	New	+$512K	0.1%	127
2020 Q3	–	Sell	-1,683	Closed	-$205K	–	177
2020 Q2	$205K	Buy	+1,683	New	+$186K	0.04%	157
2018 Q4	–	Sell	-1,725	Closed	-$212K	–	105
2018 Q3	$212K	Buy	+1,725	New	+$196K	0.06%	102
2018 Q1	–	Sell	-2,702	Closed	-$210K	–	94
2017 Q4	$210K	Sell	2,702 -19,554	-88%	-$1.33M	0.17%	88
2017 Q3	$1.36M	Buy	22,256 +2,591	+13%	+$137K	1.4%	25
2017 Q2	$905K	Buy	19,665 +10,515	+115%	+$510K	1.13%	36
2017 Q1	$396K	Sell	9,150 -15,245	-62%	-$653K	0.68%	70
2016 Q4	$944K	Sell	24,395 -9,945	-29%	-$450K	0.61%	70
2016 Q3	$1.74M	Buy	34,340 +3,380	+11%	+$168K	1.21%	30
2016 Q2	$1.41M	Buy	30,960 +21,125	+215%	+$973K	1.16%	33
2016 Q1	$389K	Buy	+9,835	New	+$390K	0.82%	70